SELECT cardiovascular trial
A 2023 NEJM trial in 17,604 adults with obesity and cardiovascular disease but no diabetes reported reduced cardiovascular events over a mean 39.8 months. Reported in the cited paper.
SourceBack to search
Weight LossMetabolic
Semaglutide
Semaglutide is an approved GLP-1 receptor agonist sold as Ozempic for type 2 diabetes, Wegovy for weight management and Rybelsus as an oral tablet. It carries a boxed warning for thyroid C-cell tumours and requires prescription and supervision.
- Lowest cost / mg
- $1.20/mg
- at Peptide Labs Inc
- Vendors listed
- 48
- In stock
- 96 of 100
- listings
- COA reports
- 72
Vendor listings
Compare Semaglutide prices.
Show prices as
99 listings · Semaglutide
In stock10mgseen 4d ago
In stock5mgseen 7d ago
In stock10mgseen 6d ago
In stock5mgseen 4d ago
In stock10mgseen 6d ago
In stock10mgseen 7d ago
In stock5mgseen 3d ago
In stock10mgseen 4d ago
In stock20mgseen 4d ago
In stock5mgseen 6d ago
In stock10mgseen 7d ago
In stock10mgseen 4d ago
In stock20mgseen 6d ago
In stock10mgseen 4d ago
In stock30mgseen 4d ago
In stock10mgseen 6d ago
In stock5mgseen 4d ago
In stock10mgseen 4d ago
In stock10mgseen 4d ago
In stock5mgseen 4d ago
Overview
What is Semaglutide?
Semaglutide is an approved GLP-1 receptor agonist sold as Ozempic for type 2 diabetes, Wegovy for weight management and Rybelsus as an oral tablet. It carries a boxed warning for thyroid C-cell tumours and requires prescription and supervision.
- Weight Management
- Glycemic Control
- Appetite Control
- Cardiovascular Risk
What the research reports
Reported benefits of Semaglutide
Outcomes described across the published Semaglutide literature and ongoing study. Read each as research context, not a promised result.
- 01
Clinically meaningful weight loss
Trials of 2.4 mg reported 14.9 percent weight loss against 2.4 percent on placebo, and 15.8 percent against 6.4 percent for liraglutide. Reported in research settings.
- 02
Appetite and satiety effects
Acts on GLP-1 receptors to reduce appetite and slow gastric emptying, which lowers food intake without deliberate restriction. Reported in research settings.
- 03
Cardiovascular risk reduction
The SELECT trial in 17,604 adults with obesity and cardiovascular disease but no diabetes reported fewer cardiovascular events across a mean 39.8 month period.
- 04
Kidney outcome study data
The FLOW trial reported slower progression of chronic kidney disease and reduced cardiovascular death risk in people with type 2 diabetes. Reported in research settings.
- 05
Liver and metabolic effects
Trial data reported resolution of steatohepatitis without worsening fibrosis in 62.9 percent of patients against 34.3 percent on placebo. Reported in research settings.
Dosage and protocol
Semaglutide dosage and protocol
The weight management titration starts at 0.25 mg weekly, rising through 0.5, 1 and 1.7 mg to a 2.4 mg target, increasing every four weeks to limit gastrointestinal side effects throughout.
- Route
- Subcutaneous injection
- Example range
- 0.25-2.4 mg
- Frequency
- Once weekly
- Timing
- Once weekly, same day, with or without food. Titrate slowly.
Clinical evidence
Clinical evidence for Semaglutide
The published record for Semaglutide, labeled by strength so you can see what is settled and what is emerging.
FLOW kidney disease trial
A NEJM trial in 3,533 people with type 2 diabetes and chronic kidney disease reported slower disease progression and lower cardiovascular death risk over 3.4 years.
SourceSOUL oral semaglutide trial
A 2025 NEJM trial in 9,650 high risk patients with type 2 diabetes reported that oral semaglutide reduced major adverse cardiovascular events against placebo. Reported in the cited paper.
SourceInteractions
How it pairs with other peptides
- Tirzepatide
- Overlapping GLP-1 agonism raises gastrointestinal side effect risk. Not combined in clinical practice.
- BPC-157 peptide
- No known negative interaction. May support gut comfort during GLP-1 therapy by a separate mechanism.
- Insulin therapy
- Combined glucose lowering raises hypoglycaemia risk and usually requires an insulin dose adjustment.
- Sulfonylureas
- Hypoglycaemia risk rises on combined therapy, so dose review by the prescribing clinician is usual.
Questions
Frequently asked questions.
What is Semaglutide?
Semaglutide is a peptide compound used in research settings. It is commonly studied for its role in weight loss, metabolic, and many researchers compare supplier quality, purity, and testing data before purchasing.
What are the research benefits of Semaglutide?
Semaglutide is often evaluated for its potential influence on signaling pathways, recovery support, and targeted research applications. Research interest varies by peptide, formulation, and study design, so buyers typically review purity, dose, and independent lab verification before choosing a source.
How does Semaglutide work?
Like other research peptides, Semaglutide is typically studied for how it interacts with specific biological pathways and receptor systems. In practice, the way it is formulated, dosed, and tested matters as much as the compound itself, which is why verified suppliers and transparent COAs are important.
Is Semaglutide for research use only?
Yes, products like Semaglutide are generally intended for research, laboratory, or educational use and are not marketed as approved human therapeutics. Always follow local laws, lab safety practices, and institutional requirements before handling or studying any peptide.
What should I look for before buying Semaglutide?
Key checks include verified COA data, peptide form and concentration, supplier reputation, stock status, and cost per mg. Comparing pricing and testing records side-by-side helps reduce the risk of buying an under-tested or misrepresented product.
